June 25 (Reuters) - Cognition Therapeutics Inc CGTX.O:
COGNITION THERAPEUTICS PROVIDES REGULATORY UPDATE ON ZERVIMESINE (CT1812) IN ALZHEIMER’S DISEASE AND DEMENTIA WITH LEWY BODIES $(DLB)$
COGNITION THERAPEUTICS INC - TO CONDUCT END-OF-PHASE 2 MEETING WITH FDA ON JULY 9, 2025
Source text: ID:nGNX2qzmb3
Further company coverage: CGTX.O
((Reuters.Briefs@thomsonreuters.com;))